Review article · 2026 · Open access
GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
The Lancet, 407(10531), 892–908 · Published 14 January 2026 · DOI 10.1016/s0140-6736(25)02105-1
In brief
“GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits” is a 2026 review article by Michael Albrecht Nauck and 3 co-authors, published in The Lancet. OpenAlex counts 157 citations as of 16 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet.
- Citations
- 157
- Most cited in
- 2026 (157)
- Field-weighted impact
- 118.18
- References
- 150
- Authors
- 4
Abstract
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1-glucagon and GLP-1-amylin) and triple (ie, GIP-GLP-1-glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026). GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet, 407(10531), 892–908. https://doi.org/10.1016/s0140-6736(25)02105-1
MLA 9
Nauck, Michael Albrecht, et al. “GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.” The Lancet, vol. 407, no. 10531, 2026, pp. 892–908. https://doi.org/10.1016/s0140-6736(25)02105-1.
Chicago
Nauck, Michael Albrecht, Katherine R. Tuttle, Matthias H. Tschöp, and Matthias Blüher. 2026. “GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.” The Lancet 407 (10531): 892–908. https://doi.org/10.1016/s0140-6736(25)02105-1.
Harvard
Nauck, M. A. et al. (2026) ‘GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits’, The Lancet, 407(10531), pp. 892–908. doi:10.1016/s0140-6736(25)02105-1.
IEEE
M. A. Nauck, K. R. Tuttle, M. H. Tschöp, and M. Blüher, “GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits,” The Lancet, vol. 407, no. 10531, pp. 892–908, 2026, doi: 10.1016/s0140-6736(25)02105-1.
BibTeX
@article{nauck2026receptor,
title = {{GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits}},
author = {Nauck, Michael Albrecht and Tuttle, Katherine R. and Tschöp, Matthias H. and Blüher, Matthias},
journal = {The Lancet},
year = {2026},
volume = {407},
number = {10531},
pages = {892--908},
doi = {10.1016/s0140-6736(25)02105-1},
url = {https://doi.org/10.1016/s0140-6736(25)02105-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- GLP-1 receptor agonists
- incretin-based therapy
- type 2 diabetes
- obesity
- cardiovascular risk
- heart failure
- albuminuria
- renal function decline
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026). GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet, 407(10531), 892–908. https://doi.org/10.1016/s0140-6736(25)02105-1
How many times has this paper been cited?
157 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Lancet: sign in and open the PDF from this page.
Who wrote this paper?
Michael Albrecht Nauck, Katherine R. Tuttle, Matthias H. Tschöp, Matthias Blüher.
What is the DOI of this paper?
10.1016/s0140-6736(25)02105-1, permanently at https://doi.org/10.1016/s0140-6736(25)02105-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.